Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial - Pratley, RE; Aroda, VR; Lingvay, I (Lancet Diabetes Endocrinol, 2018)